Krystal Biotech awarded director Mason Christopher 1,658 derivative securities in transactions dated 2026-09-14. The award was recorded at $0 per share and classified as transaction code A, identifying it as an award or grant rather than an open-market purchase or sale for investors tracking insider activity.

Key Highlights

  • The transactions were dated 14 September 2026.
  • Transaction code A identifies the activity as an award or grant.
  • The derivative securities carried a stated value of $0 per share.

Krystal Biotech, Inc. (NASDAQ: KRYS) awarded director Mason Christopher 1,658 derivative securities. The transaction represents an award to a named director, with the securities recorded under the company’s insider activity.

14 September 2026 Award Covers Derivative Securities

Krystal Biotech’s transaction record dates the activity to 14 September 2026. The stated consideration is $0 per share. The securities are associated with Christopher’s award from Krystal Biotech. The reported activity is presented as an award event, so it describes derivative securities granted to the director rather than securities acquired through an open-market purchase. The $0 per-share amount applies to the derivative securities covered by the award. Christopher is the participant associated with the transaction.